$WOK

WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026

WORK Medical Technology Group (Nasdaq: WOK) said it will conduct a 1-for-100 reverse stock split of its Class A and Class B ordinary shares effective June 18, 2026. Class A shares are expected to trade on a post-split basis that day under symbol WOK with a new CUSIP. It had 241.65M Class A shares outstanding; about 2.42M are expected after the split.

Original reporting
Published Jun 16, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026 — source image
Decision brief

The 30-second read

$WOKNeutralMed
01

Why it matters

The reverse split will reduce the number of shares outstanding by consolidating 100 shares into 1, with fractional shares rounded up, and will update the CUSIP while keeping the Nasdaq symbol WOK.

02

Market read

This is a time-specific corporate action that can drive mechanical price changes and short-term trading volatility around the June 18 open.

03

What to watch

Traders should watch for any concurrent disclosures (financing, delisting risk, or updated risk factors) not included here, since the release is limited to the split mechanics.

Relevance 6/10Novelty 8/10Timing: Effective June 18, 2026; post-consolidation trading begins at the open.

Background

WORK Medical Technology Group LTD (Nasdaq: WOK) is a China-focused medical device supplier; this release announces a reverse stock split of its Class A and Class B ordinary shares.

Company-level read

Ticker impact

$WOKNeutralMedium confidence
Context

WORK Medical announced a 1-for-100 reverse stock split effective June 18, 2026, with post-split trading at the open.

Expected impact

Near-term volatility possible around the June 18 open due to mechanical price adjustment and investor positioning.

Evidence & confidence

The filing is a concrete corporate-action event with an explicit effective date and trading start time, but it does not provide new fundamentals (earnings, guidance, financing, or regulatory outcomes).

Market effects

Limited direct read-across to medical device peers; impact is primarily company-specific corporate-action mechanics.

Minimal; the company operates in China but the event is a Nasdaq-listed corporate action.

Low; no cross-border deal, regulatory ruling, or supply-chain disruption is disclosed.

Counterpoint

The reverse split may be purely compliance/structural (e.g., maintaining listing requirements) and not necessarily a signal of worsening operations.

Key entities

  • WORK Medical Technology Group LTD

    Nasdaq-listed medical device supplier announcing a 1-for-100 reverse stock split effective June 18, 2026.

  • VStock Transfer, LLC

    Named transfer agent for shareholder questions regarding the reverse stock split.

Related articles

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$ALBMed

Albemarle has surprising new reason to rally

Mizuho upgraded Albemarle (ALB) to Outperform, citing growing demand for lithium in battery energy storage systems (BESS). The firm raised its 2027 lithium demand estimate by 10% and increased ALB's price target to $130. Albemarle's Q2 earnings showed strong growth in Energy Storage sales and EBITDA, driven by higher lithium prices. The company's outlook highlights the impact of lithium pricing on its financial performance.

$BXMed

Blackstone’s $100 billion India bet signals long

Blackstone plans to double its investment in India to $100 billion over five years, citing long-term growth prospects. The firm's COO highlights India's strong capital markets. Fairfax Financial Holdings also invested $5.6 billion in IDBI Bank. India's economic formalization, infrastructure investments, and renewable energy expansion have boosted productivity and capital market activity, with significant increases in equity and bond issuances.

$GSKMed

GSK (GSK) Reports Promising Phase Ib Data for Risvutatug Rezetec

GSK reported positive Phase Ib results for risvutatug rezetecan, an antibody-drug conjugate for relapsed extensive-stage small cell lung cancer, with a 61% ORR at 8 mg/kg dose. The company has a 3.6% dividend yield, a 39% payout ratio, and a GF Score of 78/100. GSK is fairly valued with a GF Value of $45.26 vs. market price of $49.51. Guru activity is mixed, with 15 holding, 10 trimming, and 6 adding positions.